Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
26.1M
-
Shares change
-
+54.8K
-
Total reported value, excl. options
-
$47.6M
-
Value change
-
+$964K
-
Put/Call ratio
-
0
-
Number of buys
-
24
-
Number of sells
-
-17
-
Price
-
$1.82
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q2 2020
58 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q2 2020.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.1M shares
of 193M outstanding shares and own 13.51% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (6.87M shares), COWEN AND COMPANY, LLC (4.33M shares), MORGAN STANLEY (3.35M shares), VANGUARD GROUP INC (1.83M shares), ADVISOR GROUP HOLDINGS, INC. (1.77M shares), GOLDMAN SACHS GROUP INC (1.66M shares), CITADEL ADVISORS LLC (1.35M shares), Hudson Bay Capital Management LP (975K shares), PRIMECAP MANAGEMENT CO/CA/ (500K shares), and BANK OF MONTREAL /CAN/ (466K shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.